Guest article by Ravi Ramasamy
After spending a decade of time working in the Asia Pac reconstructive markets with three major orthopedic device leaders, I decided to write my first article during this time of need. The Asia Pac recon implant business in 2019 was estimated at $2.8 billion. Post COVID-19, this revenue may plunge to $1.5B in 2020. An immediate upsurge in joint replacement procedures post COVID-19 is unlikely as patients show reluctancy for elective procedures until a vaccination or permanent remedy is in place.
Social behaviors influence treatment decisions
COVID-19 imp...
